

Medical Prior Authorization pemetrexed products

Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

Brand Name	Generic Name
Alimta	pemetrexed disodium
Axtle	pemetrexed dipotassium
Pemfexy	pemetrexed diacid
Pemrydi RTU	pemetrexed disodium

Indications

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-approved Indications¹⁻⁵

Non-squamous non-small cell lung cancer (NSCLC)

- In combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous NSCLC, with no EGFR or ALK genomic tumor aberrations.
- In combination with cisplatin for the initial treatment of patients with locally advanced or metastatic, non-squamous, NSCLC.

- As a single agent for the maintenance treatment of patients with locally advanced or metastatic, non-squamous NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy.
- As a single agent for the treatment of patients with recurrent, metastatic non-squamous, NSCLC after prior chemotherapy.

Limitations of Use

Pemetrexed is not indicated for the treatment of patients with squamous cell, NSCLC.

Mesothelioma

In combination with cisplatin, for the initial treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curative surgery.

Compendial Uses^{6,7}

- Bladder cancer
- Pleural mesothelioma
- Peritoneal mesothelioma
- Pericardial mesothelioma
- Tunica vaginalis testis mesothelioma
- Nonsquamous non-small cell lung cancer (NSCLC)
- Ovarian cancer, fallopian tube cancer, and primary peritoneal cancer: epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer, carcinosarcoma (malignant mixed Müllerian tumors), clear cell carcinoma of the ovary, grade 1 endometrioid carcinoma, low-grade serous carcinoma/ovarian borderline epithelial tumor (low malignant potential), and mucinous carcinoma of the ovary
- Primary central nervous system (CNS) lymphoma
- Thyroid carcinoma
- Thymomas and thymic carcinomas
- Cervical cancer
- Vaginal cancer

All other indications are considered experimental/investigational and not medically necessary.

Exclusions

Coverage will not be provided for members with squamous cell NSCLC.

Coverage Criteria

Bladder Cancer^{7,8}

Authorization of 6 months may be granted for treatment of locally advanced, metastatic, or relapsed transitional cell urothelium cancer, as second-line treatment.

Pleural or Peritoneal Mesothelioma^{1-6,9}

Authorization of 6 months may be granted for treatment of pleural or peritoneal mesothelioma, including pericardial mesothelioma and tunica vaginalis testis mesothelioma, when any of the following criteria are met:

- The requested medication will be used as a single agent or in combination with cisplatin or carboplatin.
- The requested medication will be used in combination with bevacizumab or durvalumab (Imfinzi) and either cisplatin or carboplatin.
- The requested medication will be used as first-line therapy in combination with pembrolizumab and platinum chemotherapy.

Non-Small Cell Lung Cancer (Non-Squamous Histology)¹⁻⁶

Authorization of 6 months may be granted for treatment of non-squamous non-small cell lung cancer (including leptomeningeal metastases).

Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer^{6,7}

Authorization of 6 months may be granted for treatment of persistent or recurrent epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer, carcinosarcoma (malignant mixed Müllerian tumors), clear cell carcinoma of the ovary, grade 1 endometrioid carcinoma, low-grade serous carcinoma/ovarian borderline epithelial tumor (low malignant potential), or mucinous carcinoma of the ovary, as single agent therapy.

Primary Central Nervous System (CNS) Lymphoma⁶

Authorization of 6 months may be granted for treatment of primary CNS lymphoma, as a single agent.

Thyroid Cancer⁶

Authorization of 6 months may be granted for treatment of progressive and/or symptomatic papillary or follicular thyroid carcinoma when all of the following criteria are met:

- Disease is unresectable or metastatic.
- Disease is not amenable to radioactive iodine (RAI) therapy.

- The requested medication will be used in combination with carboplatin.

Authorization of 6 months may be granted for treatment of progressive and/or symptomatic oncocytic/Hürthle cell thyroid carcinoma when all of the following criteria are met:

- Disease is unresectable or metastatic.
- The requested medication will be used in combination with carboplatin.

Authorization of 6 months may be granted for treatment of anaplastic carcinoma when all of the following criteria are met:

- Disease is metastatic.
- The requested medication will be used in combination with carboplatin after disease progression following prior treatment.

Thymomas and Thymic Carcinomas^{6,7}

Authorization of 6 months may be granted for treatment of thymoma or thymic carcinoma, as a single agent.

Cervical Cancer^{6,7}

Authorization of 6 months may be granted for treatment of persistent, recurrent, or metastatic cervical cancer.

Vaginal Cancer⁶

Authorization of 6 months may be granted for subsequent treatment of recurrent or metastatic vaginal cancer when used as a single agent.

Continuation of Therapy

Authorization of 6 months (up to 24 months total for use with pembrolizumab for pleural or peritoneal mesothelioma including pericardial mesothelioma and tunica vaginalis testis mesothelioma) may be granted for continued treatment in members requesting reauthorization for an indication in the coverage criteria section when there is no evidence of unacceptable toxicity or disease progression while on the current regimen.

References

1. Alimta [package insert]. Indianapolis, IN: Lilly USA, LLC; May 2023.
2. Pemfexy [package insert]. Woodcliff Lake, NJ: Eagle Pharmaceuticals, Inc.; December 2022.
3. Pemetrexed disodium [package insert]. Princeton, NJ: Dr. Reddy's Laboratories Inc.; September 2022.
4. Pemrydi RTU [package insert]. Ahmedabad, India: Zydus Lifesciences Limited; November 2024.
5. Axtle [package insert]. Parsippany, NJ: Avyxa Pharma, LLC; June 2025.

Reference number(s)
1900-A

6. The NCCN Drugs & Biologics Compendium® © 2025 National Comprehensive Cancer Network, Inc. Available at: <https://www.nccn.org>. Accessed July 16, 2025.
7. Pemetrexed. Lexi-Drugs. UpToDate Lexidrug. UpToDate Inc. <https://online.lexi.com>. Accessed July 21, 2025.
8. CVS Caremark Clinical Programs Review: State of CT review; March 2018.
9. Durvalumab. Merative Micromedex. Merative. Ann Arbor, MI. Available at <https://www.micromedexsolutions.com> Accessed July 16, 2025.